Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Irhythm Technologies ( (IRTC) ) has issued an announcement.
On October 29, 2025, iRhythm Technologies’ Board of Directors approved an amended Executive Change in Control and Severance Policy to enhance severance benefits for executives in certain termination scenarios, aligning with market practices and retaining talent. Additionally, iRhythm reported a strong financial performance for Q3 2025, with a 30.7% revenue increase driven by demand for its Zio services and operational efficiencies, positioning the company for continued growth and leadership in cardiac monitoring.
The most recent analyst rating on (IRTC) stock is a Hold with a $187.00 price target. To see the full list of analyst forecasts on Irhythm Technologies stock, see the IRTC Stock Forecast page.
Spark’s Take on IRTC Stock
According to Spark, TipRanks’ AI Analyst, IRTC is a Neutral.
Irhythm Technologies’ overall stock score is driven by strong earnings call sentiment and positive technical indicators, offset by weak valuation due to negative profitability metrics. Financial performance shows promise with revenue growth and cash flow improvements, but high leverage and operating expenses remain challenges.
To see Spark’s full report on IRTC stock, click here.
More about Irhythm Technologies
iRhythm Technologies, Inc. is a leading digital healthcare company that focuses on creating solutions to detect, predict, and prevent disease. The company combines wearable biosensors and cloud-based data analytics with proprietary algorithms to provide clinically actionable information from heart data, aiming to deliver better health outcomes.
Average Trading Volume: 424,288
Technical Sentiment Signal: Buy
Current Market Cap: $5.95B
Learn more about IRTC stock on TipRanks’ Stock Analysis page.